Welcome to our dedicated page for Ptc Therapeutics SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PTC Therapeutics, Inc. (PTCT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation listed on the Nasdaq Global Select Market under the symbol PTCT, PTC uses SEC reports to communicate material events, financial results and key agreements related to its rare disease biopharmaceutical business.
Among the filings, investors can find Form 8-K current reports detailing quarterly financial results, such as revenue from Sephience (sepiapterin), the Duchenne muscular dystrophy franchise (Translarna and Emflaza), and royalty and collaboration revenue including Evrysdi (risdiplam). 8-K filings also describe significant corporate events, including FDA approvals like the U.S. approval of Sephience for phenylketonuria (PKU), regulatory correspondence such as a Complete Response Letter for vatiquinone in Friedreich’s ataxia, and material agreements like the Rights Satisfaction Agreement with former Censa securityholders related to sepiapterin net sales payments.
Through its periodic reports (such as Forms 10-K and 10-Q, when available), PTC Therapeutics provides more extensive information on its business, risk factors, R&D and SG&A expenses, cash position, royalty and collaboration structures, and the status of programs including Translarna, Emflaza, Sephience, votoplam, vatiquinone, Upstaza/Kebilidi, Tegsedi and Waylivra. These filings also confirm the company’s incorporation in Delaware and its principal executive offices in Warren, New Jersey.
Stock Titan enhances access to PTCT filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand revenue composition, major agreements, regulatory developments and forward-looking statements. Real-time updates from EDGAR mean new 8-Ks, 10-Qs, 10-Ks and other forms appear promptly, while Form 4 insider transaction reports and proxy materials, when filed, can offer additional insight into equity awards, executive compensation and ownership changes.
By using this filings page, investors and researchers can review the official record of how PTC Therapeutics describes its rare disease portfolio, collaborations, financial performance and risks in its own words to U.S. regulators.
PTC Therapeutics officer Neil Gregory Almstead reported automatic sales of company stock tied to restricted stock unit (RSU) vesting. On January 6, 2026, he sold 1,279 shares of common stock at $76.95 per share directly and 54 shares at $76.95 held indirectly through his spouse. On January 7, 2026, he sold an additional 1,026 shares at $77.48 directly and 52 shares at $77.48 through his spouse.
According to the footnotes, all of these sales were made under irrevocable “sell to cover” elections to satisfy tax withholding obligations arising from the vesting of RSUs granted in 2023 and 2025. Following these transactions, Almstead beneficially owns 116,077 shares directly and 6,850 shares indirectly through his spouse.
A shareholder has filed a notice of proposed sale of 866 shares of common stock, to be sold through Fidelity Brokerage Services LLC on or about 01/08/2026 on the NASDAQ. The filing lists an aggregate market value of 66,204.92 for these shares and notes that 80,288,305 shares of the same class were outstanding at the time. The 866 shares were acquired on 01/07/2026 through restricted stock vesting from the issuer as compensation.
The notice also reports that the same seller disposed of 1,340 shares for 103,109.78 on 01/06/2026 and 642 shares for 49,744.60 on 01/07/2026. By signing, the seller represents that they are not aware of any undisclosed material adverse information about the issuer’s operations.
A Rule 144 filer plans to sell 3,148 common shares of an issuer with ticker PTCT through Fidelity Brokerage Services LLC. The planned sale has an aggregate market value of 240,905.34, is listed under the NASDAQ exchange, and is targeted for 01/08/2026.
The shares to be sold were acquired on 01/05/2026 through restricted stock vesting from the issuer as compensation. The notice also lists earlier sales by Eric Pauwels over the past three months, including 40,290 common shares sold on 12/17/2025 for 3,038,755.33, along with several smaller transactions in December 2025 and early January 2026.
A PTCT shareholder, Matthew Klein, filed a Form 144 notice to sell PTCT common stock under Rule 144. The notice covers 2,514 common shares to be sold through Fidelity Brokerage Services LLC on or about 01/08/2026 on the NASDAQ market. These shares were acquired on 01/07/2026 via restricted stock vesting from the issuer as compensation.
The filing also lists prior PTCT common stock sales by Matthew Klein during the past three months, including 3,428 shares sold on 12/02/2025 for gross proceeds of $271,062.93 and 8,089 shares sold on 12/30/2025 for $619,921.55, along with additional sales on 01/06/2026 and 01/07/2026.
PTCT has a Form 144 notice covering the intended sale of 59 shares of common stock through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of $4,510.50 and an approximate sale date of January 8, 2026.
The 59 shares were acquired on January 7, 2026 via restricted stock vesting from the issuer as compensation. The filing also lists recent sales in the past three months by individuals named Neil G. Almstead and Zheng Y. Almstead, including 35,572 shares sold on November 24, 2025 for $2,852,153.65, 71,928 shares on November 25, 2025 for $6,001,524.59, and several smaller transactions on January 6–7, 2026 with proceeds ranging from $4,029.16 to $98,415.98.
An insider has filed a notice of intent to sell 881 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of 67,351.66. The issuer reports 80,288,305 shares of this class outstanding, and the approximate sale date is 01/08/2026 on NASDAQ.
The 881 shares to be sold were acquired on 01/07/2026 via restricted stock vesting from the issuer as compensation. Over the past three months, Neil G. Almstead has sold multiple blocks of common shares, including 35,572 shares on 11/24/2025 for 2,852,153.65, 71,928 shares on 11/25/2025 for 6,001,524.59, 1,279 shares on 01/06/2026 for 98,415.98, and 1,026 shares on 01/07/2026 for 79,498.38. Zheng Y. Almstead sold 54 shares on 01/06/2026 for 4,155.17 and 52 shares on 01/07/2026 for 4,029.16.
An affiliate of PTCT filed a notice of proposed stock sales under Rule 144. The filer intends to sell 1,454 shares of common stock through Fidelity Brokerage Services LLC on or about 01/08/2026, with an indicated aggregate market value of $111,156.99. These shares relate to restricted stock that vested on 01/07/2026 and were received as compensation from the issuer on that date.
The notice also lists prior sales over the last three months by Eric Pauwels, including multiple transactions in common stock between 12/17/2025 and 01/07/2026 with individual gross proceeds such as $3,038,755.33 and $1,584,387.54. The filing states that the person for whose account the securities are to be sold represents that they are not aware of undisclosed material adverse information about the issuer’s operations.
An affiliate of PTCT has filed a Form 144 notice to potentially sell 1,034 shares of common stock through Fidelity Brokerage Services on 01/08/2026, with an aggregate market value of $79,048.37. The filing notes that 80,288,305 shares of common stock were outstanding and that the shares to be sold arose from restricted stock vesting on 01/07/2026 as compensation from the issuer.
Over the prior three months, the same seller, Christine Utter, reported selling 1,381 shares of common stock for gross proceeds of $106,264.64 on 01/06/2026 and 1,235 shares for $95,692.49 on 01/07/2026. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer’s operations.
PTC Therapeutics insider files to sell additional shares under Rule 144. The filing covers a planned sale of 1,286 shares of common stock through Fidelity Brokerage Services on or about
Over the past three months, Mark Boulding has already sold 11,696 shares of common stock in four transactions, generating total gross proceeds of about
A holder named Mark Boulding has filed a notice under Rule 144 to sell 2,747 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of
The 2,747 shares were acquired on